{"id":"celsentri","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Pyrexia"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Celsentri (maraviroc) binds to the CCR5 chemokine receptor on the surface of CD4+ T cells and blocks the attachment and entry of CCR5-tropic HIV strains. By selectively antagonizing this co-receptor, the drug prevents the virus from infecting cells while preserving the immune function of the targeted lymphocytes. This mechanism is distinct from reverse transcriptase or protease inhibitors and represents an entry/fusion inhibitor class.","oneSentence":"Celsentri is a CCR5 antagonist that blocks the CCR5 co-receptor on CD4+ T cells, preventing HIV entry and infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:19.098Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced patients with CCR5-tropic virus"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT04965662","phase":"PHASE4","title":"The Role of Home Packs of HIV PEPSE in High Risk Individuals","status":"COMPLETED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2018-01-01","conditions":"HIV-1-infection","enrollment":139},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT00864474","phase":"","title":"Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-03-31","conditions":"CCR5-tropic HIV-1 Infection","enrollment":68},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT02208037","phase":"PHASE2","title":"Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2014-08","conditions":"Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia","enrollment":279},{"nctId":"NCT02346084","phase":"PHASE1","title":"Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults","status":"COMPLETED","sponsor":"International Partnership for Microbicides, Inc.","startDate":"2015-01","conditions":"HIV/AIDS","enrollment":19},{"nctId":"NCT00935480","phase":"PHASE3","title":"IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2010-10","conditions":"HIV Infections","enrollment":17},{"nctId":"NCT02799888","phase":"PHASE2","title":"Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2014-04","conditions":"Graft-versus-host Disease, Hematopoietic Stem Cell Transplantation","enrollment":40},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01866267","phase":"PHASE4","title":"Switching Undetectables to Selzentry","status":"COMPLETED","sponsor":"St. Hope Foundation","startDate":"2013-01","conditions":"Human Immunodeficiency Virus, AIDS","enrollment":31},{"nctId":"NCT01033760","phase":"PHASE3","title":"Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2010-04","conditions":"HIV-1 Infections","enrollment":90},{"nctId":"NCT01060618","phase":"PHASE2, PHASE3","title":"Double-method Comparative Study in Order to Predict the Use of Co-receptors From Type 1 HIV: Phenotypic Study (Trofile ESTA®) and Virologic Response to a CCR5 Antagonist in the Short Term","status":"COMPLETED","sponsor":"Asociacion para el Estudio de las Enfermedades Infecciosas","startDate":"2009-05","conditions":"HIV Infections","enrollment":58},{"nctId":"NCT00850395","phase":"","title":"Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-07","conditions":"HIV-1","enrollment":79},{"nctId":"NCT00944541","phase":"PHASE2","title":"Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-09","conditions":"HIV Infection, HIV Infections","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Celsentri®","genericName":"Celsentri®","companyName":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","companyId":"centre-hospitalier-intercommunal-de-toulon-la-seyne-sur-mer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Celsentri is a CCR5 antagonist that blocks the CCR5 co-receptor on CD4+ T cells, preventing HIV entry and infection. Used for HIV-1 infection in treatment-experienced patients with CCR5-tropic virus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}